NanoViricides (NNVC) signed a Master Services Agreementwith Only Orphans Cote, a regulatory consultant firm founded by Dr. Timothy Cote. Dr. Cote and OOC will help the Company formulate its orphan drug strategy for NV-387, as well as develop relevant orphan drug designation applications and prosecute these applications at the US FDA Office of Orphan Products.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNVC:
- NanoViricides Holds 2025 Annual Stockholders Meeting
- NanoViricides reports Q3 EPS (10c) vs. (23c) last year
- NanoViricides Secures $6 Million Through Securities Offering
- NanoViricides prices 3.57M shares at $1.68 in registered direct offering
- NanoViricides receives approval to start Phase II trial of NV-387